142 related articles for article (PubMed ID: 22668122)
1. Immunomodulatory agents in myelofibrosis.
Tabarroki A; Tiu RV
Expert Opin Investig Drugs; 2012 Aug; 21(8):1141-54. PubMed ID: 22668122
[TBL] [Abstract][Full Text] [Related]
2. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy based approaches in myelofibrosis.
Masarova L; Verstovsek S; Kantarjian H; Daver N
Expert Rev Hematol; 2017 Oct; 10(10):903-914. PubMed ID: 28799436
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic approaches in myelofibrosis.
Barosi G; Rosti V; Vannucchi AM
Expert Opin Pharmacother; 2011 Jul; 12(10):1597-611. PubMed ID: 21457082
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
Mesa RA; Tefferi A
Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
[TBL] [Abstract][Full Text] [Related]
6. New drugs for the treatment of myelofibrosis.
Mesa RA
Curr Hematol Malig Rep; 2010 Jan; 5(1):15-21. PubMed ID: 20425392
[TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for the treatment of myelofibrosis.
Geyer HL; Mesa RA
Expert Opin Emerg Drugs; 2015; 20(4):663-78. PubMed ID: 26153237
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.
Castillo-Tokumori F; Talati C; Al Ali N; Sallman D; Yun S; Sweet K; Padron E; Lancet J; Komrokji R; Kuykendall AT
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e956-e960. PubMed ID: 32778513
[TBL] [Abstract][Full Text] [Related]
9. State-of-the-Art Review on Myelofibrosis Therapies.
Wang F; Qiu T; Wang H; Yang Q
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
[TBL] [Abstract][Full Text] [Related]
10. The new landscape of therapy for myelofibrosis.
Gowin K; Emanuel R; Geyer H; Mesa RA
Curr Hematol Malig Rep; 2013 Dec; 8(4):325-32. PubMed ID: 24101258
[TBL] [Abstract][Full Text] [Related]
11. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
Vallet S; Witzens-Harig M; Jaeger D; Podar K
Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
[TBL] [Abstract][Full Text] [Related]
12. Assessing new therapies and their overall impact in myelofibrosis.
Mesa RA
Hematology Am Soc Hematol Educ Program; 2010; 2010():115-21. PubMed ID: 21239780
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
Zeidner JF; Foster MC
Curr Drug Targets; 2017; 18(3):304-314. PubMed ID: 25738295
[TBL] [Abstract][Full Text] [Related]
14. Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials.
Stein BL
Curr Hematol Malig Rep; 2021 Oct; 16(5):483-489. PubMed ID: 34499329
[TBL] [Abstract][Full Text] [Related]
15. The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Pan B; Lentzsch S
Pharmacol Ther; 2012 Oct; 136(1):56-68. PubMed ID: 22796518
[TBL] [Abstract][Full Text] [Related]
16. Myelofibrosis: an update on current pharmacotherapy and future directions.
Cervantes F; Martinez-Trillos A
Expert Opin Pharmacother; 2013 May; 14(7):873-84. PubMed ID: 23514013
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of pomalidomide therapy in myelofibrosis.
Begna KH; Pardanani A; Mesa R; Litzow MR; Hogan WJ; Hanson CA; Tefferi A
Am J Hematol; 2012 Jan; 87(1):66-8. PubMed ID: 22081489
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness and safety of lenalidomide in myelofibrosis patients: a case series from the Spanish compassionate use program].
Castillo I; Ojea MA; Boqué C; Asensio A; Hermosilla MM; Blanes M;
Farm Hosp; 2013; 37(2):135-42. PubMed ID: 23789757
[TBL] [Abstract][Full Text] [Related]
19. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
Lacy MQ; Rajkumar SV
Am J Hematol; 2010 Feb; 85(2):95-6. PubMed ID: 20095057
[No Abstract] [Full Text] [Related]
[Next] [New Search]